Related Experiment Video
Updated: Feb 25, 2026
06:09
Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
Published on: June 7, 2019
9.6K
Refining Targeted Therapy Opportunities for BRAF-Mutant Melanoma
Russell W Jenkins1,2, David A Barbie3
1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Cancer Discovery
|August 3, 2017
Summary
Identifying key molecular features of resistance to BRAF/MAPK pathway inhibitors in melanoma is crucial for developing new treatments. This study reveals novel regulators of resistance through integrated genomic and functional analysis of cell lines.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Targeted therapies inhibiting the BRAF/MAPK pathway have shown efficacy in melanoma treatment.
- Acquired resistance to these therapies remains a significant clinical challenge.
- Understanding the molecular mechanisms underlying resistance is essential for improving patient outcomes.
Purpose of the Study:
- To identify molecular and cellular features associated with resistance to BRAF/MAPK pathway inhibition in melanoma.
- To uncover novel targetable regulators of resistance to MAPK pathway inhibition.
Main Methods:
- Integrated, comparative analysis of genomic and functional data.
- Utilized sensitive and resistant melanoma cell line models.
Main Results:
- Unveiled novel molecular regulators contributing to resistance against BRAF/MAPK pathway inhibitors.
- Identified specific cellular features associated with treatment resistance.
Conclusions:
- The identified regulators represent potential therapeutic targets for overcoming resistance to BRAF/MAPK inhibitors.
- Findings may guide the development of novel therapeutic strategies for melanoma patients resistant to current treatments.
Related Concept Videos
02:57Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
02:50Combination Therapies and Personalized Medicine
6.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
51
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
51
01:27Tumor Immunotherapy
2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
02:38Mitogens and the Cell Cycle
8.2K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K